文献速递病毒性肝炎

无或轻微肝纤维化丙型肝炎患者:治疗与持续病毒学应答对患者报告结局的影响

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
PubMed 文献 · Clin Infect Dis · 2018-01-01

纳入16项临床试验中1548例Metavir F0-F1期丙型肝炎患者,评估含或不含干扰素和利巴韦林方案对患者报告结局的影响。含干扰素方案治疗期间多数患者报告结局领域显著下降,不含干扰素和利巴韦林方案则改善;无论方案,12周和24周持续病毒学应答均与患者报告结局改善相关。

要点

  • 含干扰素方案治疗期间患者报告结局多数领域显著下降(-4.5至-28.7,0-100量表)。
  • 不含干扰素和利巴韦林方案治疗期间患者报告结局改善(+1.2至+10.9)。
  • 无论方案,12周和24周持续病毒学应答均与患者报告结局改善相关(+2.1至+14.7,P<.0001)。

核心结论

  • 无或轻微纤维化丙型肝炎患者接受不含干扰素和利巴韦林方案治疗,在治疗期间和持续病毒学应答后患者报告结局改善。

研究设计与样本

  • 汇总16项临床试验中Metavir F0-F1期丙型肝炎患者1548例,平均年龄46岁,男性43%,初治81%。

主要发现

  • 含干扰素方案组(n=91)治疗结束时多数患者报告结局领域显著下降(-4.5至-28.7,0-100量表)。
  • 不含干扰素但含利巴韦林方案组(n=479)治疗结束时患者报告结局轻度受损(-2.3至-8.9)(P≤.01)。
  • 不含干扰素和利巴韦林方案组(n=978)治疗期间患者报告结局改善(+1.2至+10.9)。
  • 无论方案,12周和24周持续病毒学应答均与患者报告结局改善相关(+2.1至+14.7,P<.0001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the effect of treating HCV in patients with no or minimal fibrosis (Metavir stage F0-F1) on patient-reported outcomes (PROs). METHODS: HCV-infected patients with F0-F1 from 16 clinical trials were included. PROs were collected before, during, and after treatment. RESULTS: A total of 1548 HCV-infected patients with F0-F1 were included (mean age 46 years, 43% male, 81% treatment-naive). Patients were treated with interferon (IFN) + sofosbuvir (SOF) + ribavirin (RBV) (n = 91) or SOF + RBV with or without ledipasvir (n = 479) or IFN- and RBV-free regimens with SOF + ledipasvir or SOF + velpatasvir or SOF + velpatasvir + voxilaprevir (n = 978). By the end of treatment, patients receiving IFN-containing regimens experienced significant decreases in most PRO domains (-4.5 to -28.7 on a 0-100 scale), while subjects treated with IFN-free RBV-containing regimens had a modest impairment (-2.3 to -8.9) (P ≤ .01). In contrast, treatment with regimens without IFN and RBV led to PRO improvements (+1.2 to +10.9). Regardless of the regimen, sustained virologic responses (SVRs) at 12 and 24 weeks were universally associated with PRO improvements (+2.1 to +14.7, P < .0001. CONCLUSIONS: HCV-infected subjects with no or minimal fibrosis treated with IFN- and RBV-free regimens experienced on-treatment and post-SVR PRO improvements.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Asselah T, et al. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis. 2018. PMID: 29272349. doi:10.1093/cid/cix1106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。